Targeted lung cancer niche sees a German pharma battle
But could toxicity be holding back filing plans?
FDA red and green lights: October 2024
October's US approvals included Scemblix, Vyloy and Itovebi, while Lumakras was delayed.
Clouds loom for Novartis’s MorphoSys buy
Pelabresib is delayed, and Novartis writes off $800m of the €2.7bn purchase.
